Optimizing combination treatment in the management of type 2 diabetes

References

• American Diabetes AssociationStandards in medical care in diabetesDiabetes Care200629Suppl 1S44216373931
   PubMed Web of Science ®Google Scholar
• BaileyCJTreating insulin resistance in type 2 diabetes with metformin and thiazolidinedionesDiabetes Obes Metab2005766759116219011
   PubMed Web of Science ®Google Scholar
• CampbellIWThe clinical significance of PPAR gamma agonismCurrent molecular medicine200553496315892654
   PubMed Web of Science ®Google Scholar
• CampiaUMatuskeyLAPanzaJAPeroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factorsCirculation20061138677516461819
   PubMed Web of Science ®Google Scholar
• CastanedaCDiabetes control with physical activity and exerciseNutr Clin Care20036899614692297
   PubMedGoogle Scholar
• De FeoPDi LoretoCRanchelliAExercise and diabetesActa Biomed200677Suppl 1141716921608
   PubMedGoogle Scholar
• DerosaGCiceroAFGGaddiAA comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndromeClin Ther200427445415220018
   PubMedGoogle Scholar
• DerosaGGaddiAVPicinniMNAntithrombotic effects of rosiglitazone-metfromin vs glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome)Pharmacotherapy20056374515899724
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAVLong-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trialClin Ther20052713839116291411
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAA comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndromeDiabetes Res Clin Pract20056951315955382
   PubMed Web of Science ®Google Scholar
• DerosaGGaddiAVCiccarelliLLong-term effects of glimepiride and rosiglitazone on non-conventionall cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trialJ Int Med Res2005332849415938589
   PubMed Web of Science ®Google Scholar
• DerosaGD’AngeloARagonesiPDMetabolic effect of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metforminIntern Med J200737798617229249
   PubMed Web of Science ®Google Scholar
• DormandyACharbonellBEcklandDAJSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial macroVascular Events): a randomised control trialLancet200536612798916214598
   PubMed Web of Science ®Google Scholar
• EvansJMOgstonSAEmslie-SmithARisk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metforminDiabetologia200649930616525843
   PubMed Web of Science ®Google Scholar
• FonsecaVEffect of thiazolidinediones on body weight in patients with type 2 diabetes mellitusAm J Med200311542S48S14678865
   PubMed Web of Science ®Google Scholar
• GolayAYbarraJLink between obesity and type 2 diabetesBest Pract Res Clin Endocrinol Metab2005196496316311223
   PubMed Web of Science ®Google Scholar
• HanefeldMBrunettiPSchernthanerGHOne-year glycemic control with a sulphonylurea plus pioglitazone versus a sulphonylurea plus metformin in patients with type 2 diabetesDiabetes Care200427141714693980
   PubMed Web of Science ®Google Scholar
• HundalRSInzucchiSEMetformin: new understandings, new usesDrugs20036318799412930161
   PubMed Web of Science ®Google Scholar
• HusseinZWentworthJMNankervisAJEffectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospitalMed J Aust200418132615377245
   PubMed Web of Science ®Google Scholar
• InzucchiSEOral antihyperglycemic therapy for type 2 diabetes: scientific reviewJAMA20022873607211790216
   PubMed Web of Science ®Google Scholar
• JoklRLaiminsMKleinRLPlatelet plasminogen activator inhibitor 1 in patients with type II diabetesDiabetes Care199417818237956624
   PubMed Web of Science ®Google Scholar
• KrentzAJBaileyCJOral antidiabetic agents: current role in type 2 diabetes mellitusDrugs20056538541115669880
   PubMed Web of Science ®Google Scholar
• LawrenceJMReidJTaylorGJFavorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetesDiabetes Care20042741614693964
   PubMed Web of Science ®Google Scholar
• MudaliarSChangARHenryRRThiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implicationsEndocr Pract200394061614583425
   PubMedGoogle Scholar
• NegroRDazziDHassanHPioglitazone reduces blood pressure in non-dipping diabetic patientsMinerva Endocrinol200429111715258553
   PubMedGoogle Scholar
• NestoRWBellDBonowRConsensus Statement Thiazolidinedione Use, fluid retention and congestive heart failureDiabetes Care2004272566214693998
   PubMed Web of Science ®Google Scholar
• PetriAde LusignanSWilliamsJManagement of cardiovascular risk factors in people with diabetes in primary care: Cross-sectional studyPublic Health20061206546316725165
   PubMed Web of Science ®Google Scholar
• PfutznerASchondorfTSeidelDImpact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepirideMetabolism20065520516324915
   PubMed Web of Science ®Google Scholar
• RendellMThe role of sulphonylureas in the management of type diabetes mellitusDrugs20046413395815200348
   PubMed Web of Science ®Google Scholar
• RivelineJPDanchinNLedruFSulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applicationsDiabetes Metab2003292072212909809
   PubMed Web of Science ®Google Scholar
• RobertsAWThomasAReesAPeroxisome proliferator-activated receptors-γ agonists in atherosclerosis: current evidence and future directionsCurr Opinion Lipidol20031456773
   PubMed Web of Science ®Google Scholar
• SamahaFFSzaparyPOIqbalNEffects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndromeArterioscler Thromb Vasc Biol20062614131416709957
   PubMed Web of Science ®Google Scholar
• SchnellOStandlEImpaired glucose tolerance, diabetes, and cardiovascular diseaseEndocr Pract200612Suppl 1161916627374
   PubMedGoogle Scholar
• TiikkainenMHakkinenAMKorsheninnikovaEEffects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetesDiabetes20045321697615277403
   PubMed Web of Science ®Google Scholar
• TurnerRCCullCAFrighiVGlycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospectives Diabetes Study (UKPDS) GroupJAMA1999281200501210359389
   PubMed Web of Science ®Google Scholar
• VaagAAGlycemic control and prevention of microvascular and macrovascular disease in the Steno 2 studyEndocr Pract200612Suppl 1899216627389
   PubMedGoogle Scholar
• VergesBClinical interest of PPARs ligandsDiabetes Metab20043071215029092
   PubMed Web of Science ®Google Scholar
• WeissmanPNGoldsteinBJCampbellJCRosiglitazone plus metformin combination effects on cardiovasula risk markers suggest potential cardiovascular benefits in type 2 diabetic patients (abstract n.121–OR)Diabetes2004Suppl 228
   Google Scholar
• ZieglerDType 2 diabetes as an inflammatory cardiovascular disorderCurr Mol Med200553092215892650
   PubMed Web of Science ®Google Scholar